Genetic–Epigenetic Interactions in Uterine Leiomyomas: MED12 Mutations as Predictors of Aberrant DNA Methylation
Genes · 28.07.2026 · 17 (8) · 877
DOI: 10.3390/genes17080877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 28.07.2026. Verfasst von Tayyaba Kazmi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Basic Medical Sciences, Baqai Medical University, Karachi 75340, Pakistan. Hauptthemen laut MEDLINE: Leiomyoma, DNA Methylation, Mediator Complex, Uterine Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The study was conducted to investigate the frequency of MED12 gene (rs5030619) mutations and to evaluate DNA methylation patterns in uterine leiomyomas among women at a tertiary care hospital in Karachi, Pakistan.
Methods
In this cross-sectional study, 200 women with uterine fibroids and 50 controls were recruited from tertiary care hospitals after ethical approval. Baseline data and history were collected. Serum levels of estradiol, progesterone, and FSH were measured. Genomic DNA was extracted from fibroid and myometrial tissues and analyzed using allele-specific PCR for MED12 genotyping. DNA methylation profiling was conducted to evaluate epigenetic modifications. Statistical analyses were performed using the Statistical Package for social sciences (SPSS) version 27.0.
Results
The majority of cases were aged 31–50 years, with 41.5% overweight and 24.5% obese. An increased WHR was observed in 65% of cases, compared to only 36% of controls. Serum estradiol, progesterone, and FSH levels were significantly higher in cases across all menstrual phases (p < 0.01). The MED12 A/C genotype was significantly associated with fibroid risk (OR = 11.72, 95% CI: 5.59–24.57, p < 0.001), and the C/C genotype conferred the highest risk (OR = 18.17, 95% CI: 4.00–82.54, p = 0.001). C allele was associated with increased disease susceptibility (OR = 4.65, 95% CI: 2.69–8.03, p < 0.001). Hyper-methylation was the most prevalent finding, observed in 125 cases of leiomyomas (69.4%). Multivariable logistic regression identified age (OR = 1.04, p = 0.012), BMI (OR = 1.09, p = 0.004), multiple fibroids (OR = 2.31, p = 0.005), intramural fibroid location (OR = 1.88, p = 0.041), and positive family history (OR = 2.74, p = 0.003) as significant independent predictors.
Conclusions
Uterine leiomyomas may be influenced by a combination of hormonal, metabolic, genetic, and epigenetic factors. Overall findings suggest that MED12 C allele and A/C genotype variation was significantly associated with increased DNA methylation in uterine leiomyomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Basic Medical Sciences, Baqai Medical University, Karachi 75340, Pakistan.
- Faculty of Health Sciences, Aga Khan University and Hospital, Karachi 74800, Pakistan.
- School of Biomedical Sciences, University of Plymouth, Portland Square, Plymouth PL4 8AA, UK.
ORCID-Profile: Ruqaya Nangrejo, Eraj Abbas, Rehana Rehman, Paul Laurance-Young
Zitieren
APA
Kazmi, T., Nangrejo, R., Abbas, E., Waris, N., Siddiqui, I. A., Rehman, R., & Laurance-Young, P. (2026). Genetic–Epigenetic Interactions in Uterine Leiomyomas: MED12 Mutations as Predictors of Aberrant DNA Methylation. Genes, 17(8), 877. https://doi.org/10.3390/genes17080877
Vancouver
Kazmi T, Nangrejo R, Abbas E, Waris N, Siddiqui IA, Rehman R, et al. Genetic–Epigenetic Interactions in Uterine Leiomyomas: MED12 Mutations as Predictors of Aberrant DNA Methylation. Genes. 2026;17(8):877. doi:10.3390/genes17080877
BibTeX
@article{Kazmi2026,
author = {Kazmi, Tayyaba and Nangrejo, Ruqaya and Abbas, Eraj and Waris, Nazish and Siddiqui, Iftikhar Ahmed and Rehman, Rehana and Laurance-Young, Paul},
title = {Genetic–Epigenetic Interactions in Uterine Leiomyomas: MED12 Mutations as Predictors of Aberrant DNA Methylation},
journal = {Genes},
year = {2026},
volume = {17},
number = {8},
pages = {877},
doi = {10.3390/genes17080877}
}
EUVIMED